Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: A randomized trial

JAMA

Volumn 306, Issue 12, 2011, Pages 1344-1351

  Barry, Michael J ^a   Meleth, Sreelatha ^b   Lee, Jeannette Y ^c   Kreder, Karl J ^d   Avins, Andrew L ^e   Nickel, J Curtis ^f   Roehrborn, Claus G ^g   Crawford, E David ^h   Foster, Harris E ⁱ   Kaplan, Steven A ^j   McCullough, Andrew ^k   Andriole, Gerald L ^l   Naslund, Michael J ^m   Williams, O Dale ^b   Kusek, John W ⁿ   Meyers, Catherine M ^o   Betz, Joseph M ^p   Cantor, Alan ^b   McVary, Kevin T ^q  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e DIVISION OF RESEARCH   (United States)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

^k NEW YORK UNIVERSITY   (United States)

^l WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF MARYLAND   (United States)

ⁿ NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^o National Advisory Council for Complementary and Alternative Medicine   (United States)

^p NATIONAL INSTITUTES OF HEALTH   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROSTA URGENIN UNO; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; UNCLASSIFIED DRUG;

ADULT; AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX SCORE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; CONTINENCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EYE DISEASE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; INJURY; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NOCTURIA; NORTH AMERICA; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SEXUAL FUNCTION; SIDE EFFECT; SKIN DISEASE; SLEEP QUALITY; TOOTH DISEASE; UPPER RESPIRATORY TRACT DISEASE; URINE FLOW RATE; UROGENITAL TRACT DISEASE;

EID: 80053219508     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1364     Document Type: Article

References (28)

1. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM. New diagnostic and treatment guidelines for benign prostatic hyperplasia: potential impact in the United States. Arch Intern Med. 1995; 155(5):477-481.
2. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003), chapter 1: diagnosis and treatment recommendations. J Urol. 2003;170(2 pt 1):530-547.
3. McConnell JD, Roehrborn CG, Bautista OM, et al Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. (Pubitemid 37542987)
4. Dedhia RC, McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2008;179(6):2119-2125.
5. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report. 2008;(12):1-23.
6. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. J Urol. 2000; 163(5):1408-1412. (Pubitemid 30226284)
7. Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? mechanisms of action. J Urol. 2004; 172(5 pt 1):1792-1799. (Pubitemid 39363057)
8. Maccagnano C, Salonia A, Briganti A, et al. A critical analysis of Permixon™ in the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Eur Urol Suppl. 2006;5(4):430-440. doi:10.1016/j.eursup. 2006.02.006. (Pubitemid 43340417)
9. Pais P. Potency of a novel Saw Palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II. Adv Ther. 2010;27(8):555-563.
10. Wilt T, Ishani A, Mac Donald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(3):CD001423.
11. Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;(2):CD001423.
12. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006; 354(6):557-566. (Pubitemid 43209103)
13. Avins AL, Bent S, Staccone S, et al. A detailed safety assessment of a saw palmetto extract. Complement Ther Med. 2008;16(3):147-154.
14. Lee J, Andriole G, Avins A, et al. Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia. Clin Trials. 2009; 6(6):628-636.
15. United States Pharmacopeial Convention. United States Pharmacopeia, Saw Palmetto Extract: The Official Compendia of Standards USP 33/NF28 S1 Reissue. Rockville, MD: United States Pharmacopeial Convention; 2010.
16. Barry MJ, Fowler FJ Jr, O'Leary MP, et al The Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549-1557.
17. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 1995;33 (4)(suppl):AS145-AS155.
18. O'Leary MP, Wei JT, Roehrborn CG, et al. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int. 2008;101(12):1531-1535. (Pubitemid 351704033)
19. Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of Male SexualHealth Questionnaire to assess ejaculatory dysfunction. Urology. 2007;69(5):805-809. (Pubitemid 46670268)
20. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49(6):822-830. (Pubitemid 27246947)
21. Donovan JL, Peters TJ, Abrams P, et al. Scoring the short form ICSmaleSF questionnaire. J Urol. 2000; 164(6):1948-1955.
22. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol. 1988;41(4):313-321. (Pubitemid 18089231)
23. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, et al. The National Institutes of Health Chronic Prostatitis Symptom Index: development and validation of new outcome measure. J Urol. 1999;162(2): 369-375. (Pubitemid 29434343)
24. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is perceptible to patients? J Urol. 1995;154(5):1770-1774.
25. Knottnerus JA, Bouter LM. The ethics of sample size: two-sided testing and one-sided thinking. J Clin Epidemiol. 2001;54(2):109-110. (Pubitemid 32112367)
26. Lee JY, Foster HE Jr, McVary KT, et al. Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia. J Altern Complement Med. 2011;17(5):469-472.
27. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651-658. (Pubitemid 43374725)
28. Nickel JC. The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. Curr Opin Urol. 2006;16(1):5-10. (Pubitemid 43041214)